Beth Hoffman

Company: Origami Therapeutics, Inc.

Job title: Chief Executive Officer

Seminars:

Successful Use of Phenotypic Screening for Protein Degraders for Neurodegenerative Disease 1:45 pm

Keys for high-throughput screening Expeditious characterization of hits using primary human cell models Accelerating drug discovery using PK/PD modelsRead more

day: Conference Day Two

Panel Discussion – What Do We Need To Do To Get Protein Degraders To Clinic For Treating Neurodegenerative Disease? 10:00 am

How translatable are the current models to clinic and what do we need to advance them for approved use? What are the regulatory hurdles for protein degraders in neurodegenerative disease? What lessons have been learnt by past failures in neurodegenerative drug development that can inform the success of protein degraders? Read more

day: Conference Day One